drugset / Trial / NCT01019187

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

NCT01019187

Phase 2 Completed 226 enrolled Abramson Cancer Center at Penn Medicine
RandomizedFactorialDouble-blindSupportive care

Summary

RATIONALE: Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life of cancer survivors. Armodafinil may help relieve insomnia and fatigue in patients with cancer after chemotherapy. PURPOSE: This randomized phase II trial is studying how well cognitive behavioral therapy with or without armodafinil works in treating cancer survivors with insomnia and fatigue after chemotherapy.

Timeline

Start
2009-06
Primary completion
2013-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule Oral